Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs TransMedics Group Inc — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $51.89, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPHD | TMDX | |
|---|---|---|
52-Week High | $53.55 | $150.42 |
52-Week Low | $46.96 | $61.99 |
Market Cap | — | $3.06B |
Sector | — | Technology |
Enterprise Value | — | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $51.96, down 0.65% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF focuses on high dividend yield and low volatility, offering monthly income payments of $0.21. Recent news highlights SPHD's 4.4% yield appeal amid market volatility, though some analysts question its total return potential compared to peers like SCHD.
The outlook remains balanced between income generation and growth limitations. SPHD provides stable monthly dividends attractive for conservative investors, but faces competition from higher-quality dividend ETFs. Key risks include exposure to yield traps and weaker drawdown recovery, requiring careful consideration of total return objectives versus income needs.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
